%0 Journal Article
%A Peng, Tianping
%A Ma, Xiujian
%A Hua, Wei
%A Wang, Changwen
%A Chu, Youjun
%A Sun, Meng
%A Fermi, Valentina
%A Hamelmann, Stefan
%A Lindner, Katharina
%A Shao, Chunxuan
%A Zaman, Julia
%A Tian, Weili
%A Zhuo, Yue
%A Harim, Yassin
%A Stöffler, Nadja
%A Hammann, Linda
%A Xiao, Qungen
%A Jin, Xiaoliang
%A Warta, Rolf
%A Lotsch, Catharina
%A Zhuang, Xuran
%A Feng, Yuan
%A Fu, Minjie
%A Zhang, Xin
%A Zhang, Jinsen
%A Xu, Hao
%A Qiu, Fufang
%A Xie, Liqian
%A Zhang, Yi
%A Zhu, Wei
%A Du, Zunguo
%A Salgueiro, Lorena
%A Schneider, Mark
%A Eichhorn, Florian
%A Lefevre, Arthur
%A Pusch, Stefan
%A Grinevich, Valery
%A Ratliff, Miriam
%A Loges, Sonja
%A Bunse, Lukas
%A Sahm, Felix
%A Xiang, Yangfei
%A Unterberg, Andreas
%A von Deimling, Andreas
%A Platten, Michael
%A Herold-Mende, Christel
%A Wu, Yonghe
%A Liu, Haikun
%A Mao, Ying
%T Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy.
%J Cell stem cell
%V 32
%N 4
%@ 1934-5909
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-00346
%P 652-669.e11
%D 2025
%Z DKFZ-ZMBH Alliance / #EA:A240# / HI-TRON / 2025 Apr 3;32(4):652-669.e11
%X Tumor organoids are important tools for cancer research, but current models have drawbacks that limit their applications for predicting response to therapy. Here, we developed a fast, efficient, and complex culture system (IPTO, individualized patient tumor organoid) that accurately recapitulates the cellular and molecular pathology of human brain tumors. Patient-derived tumor explants were cultured in induced pluripotent stem cell (iPSC)-derived cerebral organoids, thus enabling culture of a wide range of human tumors in the central nervous system (CNS), including adult, pediatric, and metastatic brain cancers. Histopathological, genomic, epigenomic, and single-cell RNA sequencing (scRNA-seq) analyses demonstrated that the IPTO model recapitulates cellular heterogeneity and molecular features of original tumors. Crucially, we showed that the IPTO model predicts patient-specific drug responses, including resistance mechanisms, in a prospective patient cohort. Collectively, the IPTO model represents a major breakthrough in preclinical modeling of human cancers, which provides a path toward personalized cancer therapy.
%K brain metastasis (Other)
%K glioblastoma (Other)
%K patient tumor organoid (Other)
%K predictive patient model (Other)
%K temozolomide (Other)
%K tumor heterogeneity (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39938519
%R 10.1016/j.stem.2025.01.002
%U https://inrepo02.dkfz.de/record/298907